Fol. Biol. 2013, 59, 217-224
https://doi.org/10.14712/fb2013059060217
Correlated Increase of Omentin-1 and Adiponectin by Exenatide, Avandamet and Dietary Change in Diet-Induced Obese Rats
References
1. 2009) Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc. Health Risk Manag. 5, 141-151.
< , A. H. (https://doi.org/10.2147/VHRM.S4664>
2. 2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23, 57-63.
< , E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., Muggeo, M. (https://doi.org/10.2337/diacare.23.1.57>
3. 2012) Metformin and its clinical use: new insights for an old drug in clinical practice. Arch. Med. Sci. 8, 907-917.
< , A. F., Tartagni, E., Ertek, S. (https://doi.org/10.5114/aoms.2012.31622>
4. 2010) Chronic administration of the glucagonlike peptide1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. Diabetes 59, R2653-2661.
< , B. P., Stanhope, K. L., Graham, J. L., Baskin, D. G., Griffen, S. C., Nilsson C, Sams, A., Knudsen, L. B, Raun, K., Havel, P. J. (https://doi.org/10.2337/db09-1564>
5. 2007) Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56, 655-661.
< , C. M., Yang, R. Z., Lee, M. J., Glynn, N. M., Yu, D. Z., Pray J, Ndubuizu, K., Patil, S., Schwartz, A., Kligman, M., Fried, S. K., Gong, D. W., Shuldiner, A. R., Pollin, T. I., McLenithan, J. C. (https://doi.org/10.2337/db06-1506>
6. 2008) A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol. Can. J. Cardiol. 24, e65-69.
< , M., Braga, M. B., Verma S. (https://doi.org/10.1016/S0828-282X(08)70685-8>
7. 2010) Reversal of obesity and insulin resistance by a nonpeptidic glucagonlike peptide1 receptor agonist in dietinduced obese mice. PLoS One 5, e14205.
< , M., Su, H., Gao, W., Johansson, S. M., Liu, Q., Wu, X., Liao, J., Young, A. A., Bartfai, T., Wang, M. W. (https://doi.org/10.1371/journal.pone.0014205>
8. 2011) Effects of rosiglitazone/ metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 119, 63-68.
< , N. P., Kapelouzou, A., Tsanikidis, H., Vitta, I., Liapis, C. D., Sailer, N. (https://doi.org/10.1055/s-0030-1265174>
9. 2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116, 1784-1792.
< , T., Yamauchi, T., Kubota, N., Hara, K., Ueki, K., Tobe, K. (https://doi.org/10.1172/JCI29126>
10. 2008) Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obes. Metab. 10, 921-930.
< , L., Yang, G., Li, Q., Tan, X., Liu, H., Tang, Y., Boden, G. (https://doi.org/10.1111/j.1463-1326.2007.00832.x>
11. 2010) Circulating omentin concentration increases after weight loss. Nutr Metab (Lond). 7, 27.
< , J. M., Catalán, V., Ortega, F., Gómez-Ambrosi, J., Ricart, W., Frühbeck, G., FernándezReal, J. M. (https://doi.org/10.1186/1743-7075-7-27>
12. 2006) Effects of low- carbohydrate vs lowfat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch. Intern. Med. 166, 285-293.
< , A. J., Nordmann, A., Briel, M., Keller, U., Yancy, W. S. Jr., Brehm, B. J., Bucher, H. C. (https://doi.org/10.1001/archinte.166.3.285>
13. 2010) Effects of aerobic training on serum omentin1 and cardiometabolic risk factors in overweight and obese men. J. Sports Sci. 28, 993-998.
< , A., Asghari, M., Ghorbani, A. (https://doi.org/10.1080/02640414.2010.484070>
14. 2011) Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring) 19, 2310-2315.
< , P., Jogi, M., Muthupillai, R., Krishnamurthy, R., Samson, S. L., Bajaj, M. (https://doi.org/10.1038/oby.2011.152>
15. 2012) Omentin as a novel biomarker of metabolic risk factors. Diabetol. Metab. Syndr. 26, 37.
< , R., Ouchi, N., Takahashi, R., Terakura, Y., Ohashi, K., Keda, N., Higuchi, A., Terasaki, H., Kihara, S., Murohara, T. (https://doi.org/10.1186/1758-5996-4-37>
16. 2012) Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Biochem. Biophys. Res. Commun. 425, 304-308.
< , D., Fujiwara, Y., Komohara, Y., Mizuta, H., Takeya, M. (https://doi.org/10.1016/j.bbrc.2012.07.086>
17. 2011) Effect of diet on adiponectin levels in blood. Nutr. Rev. 69, 599-612.
< , F. M., de Almeida, J. C., Feoli, A. M. (https://doi.org/10.1111/j.1753-4887.2011.00414.x>
18. 2012) Plasma adiponectin levels in women with polycystic ovary syndrome: impact of Metformin treatment in a casecontrol study. Diabetes Metab. Syndr. 6, 207-211.
< , S., Akhtar, N., Ahmad, J. (https://doi.org/10.1016/j.dsx.2012.05.013>
19. 2008) Omentin-1, a novel adipokine, is decreased in overweight insulinresistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin1 by insulin and glucose. Diabetes 57, 801-808.
< , B. K., Adya, R., Farhatullah, S., Lewandowski, K. C., O’Hare, P., Lehnert, H., Randeva, H. S. (https://doi.org/10.2337/db07-0990>
20. 2010) Metformin treatment may increase omentin1 levels in women with polycystic ovary syndrome. Diabetes 59, 3023-3031.
< , B. K., Adya, R., Farhatullah, S., Chen, J., Lehnert, H., Randeva, H. S. (https://doi.org/10.2337/db10-0124>
21. 2010) Exenatide in type 2 diabetes. Lancet 376, 1052-1053.
< , F., Chinello, M. (https://doi.org/10.1016/S0140-6736(10)61485-7>
22. 2003) Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796–1808.
< , S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R., L., Ferrante, A., W. (https://doi.org/10.1172/JCI200319246>
23. 2011) Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in NAFLD. Hepatogastroenterology 58, 1703-1707.
, D., Huang, X. D., Yuan, J., P., Wu, J., Fan, Y., Luo, H. S., Yang, Y. H. (
24. 2011a) Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 119, 257-263.
< , P., Liu, D., Long, M., Ren, Y., Pang, J., Li, R. (https://doi.org/10.1055/s-0030-1269912>
25. 2011b) Effects of the long-acting human glucagon-like peptide1 analog liraglutide on plasma omentin1 levels in patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 92, 368-374.
< , P., Li, L., Yang, M., Liu, D., Liu, H., Boden, G., Yang, G. (https://doi.org/10.1016/j.diabres.2011.02.030>
26. 2006) Identification of omentin as a novel depot- specific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab. 290, E1253-1261.
< , R. Z., Lee, M. J., Hu, H., Pray, J., Wu, H. B., Hansen, B. C., Shuldiner, A. R., Fried, S. K., McLenithan, J. C., Gong, D.W. (https://doi.org/10.1152/ajpendo.00572.2004>